EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology

Laureen de Bever, Sorraya Popal, Jord van Schaik, Baron Rubahamya, Floris L van Delft, Greg M Thurber iD, Sander S van Berkel

Bioconjugate Chemistry · 2023

DOI: 10.1021/acs.bioconjchem.2c00611 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2023. Verfasst von Laureen de Bever und 6 weiteren Autor:innen. Beteiligte Einrichtung: Synaffix BV, Kloosterstraat 9, 5349 AB Oss, The Netherlands. Hauptthemen laut MEDLINE: Immunoconjugates, Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GlycoConnect technology can be readily adapted to provide different drug-to-antibody ratios (DARs) and is currently also evaluated in various clinical programs, including ADCT-601 (DAR2), MRG004a (DAR4), and XMT-1660 (DAR6). While antibody-drug conjugates (ADCs) typically feature a DAR2-8, it has become clear that ADCs with ultrapotent payloads (e.g., PBD dimers and calicheamicin) can only be administered to patients at low doses (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesCarcinoma, HepatocellularLiver NeoplasmsAntineoplastic AgentsHumansTissue DistributionTechnology

Substanzen

ImmunoconjugatesAntineoplastic Agents

Autor:innen und Institutionen

  • Synaffix BV, Kloosterstraat 9, 5349 AB Oss, The Netherlands.
  • Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States.
  • Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States.

ORCID-Profile: Greg M Thurber

Förderung

  • NIGMS NIH HHS
  • National Institutes of Health

Zitieren

APA

de Bever, L., Popal, S., van Schaik, J., Rubahamya, B., van Delft, F. L., Thurber, G. M., & van Berkel, S. S. (2023). Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.2c00611

Vancouver

de Bever L, Popal S, van Schaik J, Rubahamya B, van Delft FL, Thurber GM, et al. Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology. Bioconjugate Chemistry. 2023. doi:10.1021/acs.bioconjchem.2c00611

BibTeX
@article{deBever2023,
  author = {de Bever, Laureen and Popal, Sorraya and van Schaik, Jord and Rubahamya, Baron and van Delft, Floris L and Thurber, Greg M and van Berkel, Sander S},
  title = {Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology},
  journal = {Bioconjugate Chemistry},
  year = {2023},
  doi = {10.1021/acs.bioconjchem.2c00611}
}
Kostenlos starten →